Of the total amount, SII will get Rs 3,000 crore, while Bharat Biotech will get around Rs 1,500 crore, multiple sources confirmed
manufacturers Serum Institute of India
(SII) and Bharat Biotech
will together get Rs 4,500 crore from the Centre as suppliers’ credit, sources in the know said. This will be an upfront payment for the vaccine
doses that these two companies will supply to the government. At Rs 150 per dose, excluding taxes, this roughly works out to be 300 million doses.
Of the total amount, SII will get Rs 3,000 crore, while Bharat Biotech
will get around Rs 1,500 crore, multiple sources confirmed. Both SII and Bharat Biotech
refused to comment.
The Department of Expenditure has agreed to relax the General Financial Rules and permit the Ministry of Health to make an advance payment to the two vaccine
manufacturers, without any bank guarantee. “So, basically, they get money to supply vaccines in the future and they get it as an advance, but they don’t have to furnish bank guarantees for that advance,” said a government official.
In the first place, the government doesn’t pay in advance for the supply, but even if it does in certain cases, it insists on bank guarantees in accordance with the General Financial Rules.
“This is a relaxation that has been given to the health ministry. The ministry will make payment, and not the finance ministry,” said the official.
The relaxation, he added, would help companies get immediate cash flow support without any cost to them.
SII CEO Adar Poonawalla had sought Rs 3,000 crore from the government as grant to enable the firm to dedicate another plant to make the Oxford-AstraZeneca vaccine (Covishield).
He had told Business Standard that “Otherwise, it is difficult for us to ramp up (vaccine production) because we have invested thousands of crores already and have borrowed Rs 1,500 crore in April to manage the additional opex (operating expense) requirements of these large volumes”.
A senior government officer, however, said it was not possible to give a grant to a private company. “We cannot give grants to a private agency. They wanted cash and this is the only sensible way we can provide cash to a profit-making company, which is not doing it for charity and is admittedly making considerable profits. So the question of giving grants does not arise.”
Sources indicated that in the absence of a grant, SII would continue its planned scale-up of Covishield production. From 70 million doses per month now, it would be scaled up to 100 million doses a month by July.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.